Active	Status	Sponsor type	Region	Phase	Filter
4 Active 2 Inactive 6 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Junius, Harald
ARASAFE, NCT05676203: A Trial Comparing Docetaxel 75 mg/m2 (3w) Versus Docetaxel 50 mg/m2 (2w) in Combination With Darolutamide + ADT in mHSPC Patients	Recruiting	3	250	Europe	Standard ADT (androgen deprivation therapy), Standard Darolutamide, Docetaxel	Jena University Hospital, Bayer	Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)	07/25	01/27
Grimm, Marc-Oliver
NCT02106572 / 2013-003446-16: Therapeutic Instillation of Mistletoe	Recruiting	3	548	Europe, RoW	abnobaVISCUM 900, viscum album extract, mistletoe extract, abnobaVISCUM, Mitomycin C, MMC, Mitomycin	Abnoba Gmbh	Superficial Bladder Cancer	06/28	12/28
ARASAFE, NCT05676203: A Trial Comparing Docetaxel 75 mg/m2 (3w) Versus Docetaxel 50 mg/m2 (2w) in Combination With Darolutamide + ADT in mHSPC Patients	Recruiting	3	250	Europe	Standard ADT (androgen deprivation therapy), Standard Darolutamide, Docetaxel	Jena University Hospital, Bayer	Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)	07/25	01/27
TITAN-TCC, NCT03219775 / 2016-004857-33: Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Transitional Cell Carcinoma	Active, not recruiting	2	169	Europe	Nivolumab/Ipilimumab, Opdivo/Yervoy	AIO-Studien-gGmbH, Bristol-Myers Squibb	Transitional Cell Carcinoma, Advanced Cancer, Metastatic Cancer	09/21	02/23